Could a diabetes pill help HIV patients shed pounds?
NCT ID NCT07336797
First seen Jan 18, 2026 · Last updated May 20, 2026 · Updated 21 times
Summary
This study tests whether empagliflozin, a drug used for diabetes, can help people with HIV who are overweight or obese lose weight and improve their metabolism. About 66 adults with HIV on a specific type of antiretroviral therapy will take either the drug or a placebo for 6 months. The main goal is to see if the drug leads to weight loss and better cholesterol and blood sugar levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Faculty of Pharmacy, Cairo University | Kasr El-Aini, Cairo
RECRUITINGCairo, 11562, Egypt
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.